Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung

Study Overview
=================
Brief Summary
-----------------
To describe the overall survival of advanced NSCLC in Latin America.

Detailed Description
-----------------
To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC To describe treatment responses, progression and survival times. To describe reasons for treatment discontinuation To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival; To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.

Official Title
-----------------
Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18 years or older; Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time); Histologically or cytologically confirmed advanced NSCLC: Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery); Stage IV metastatic disease (de novo or distant relapse) Any NSCLC histological subtype and molecular mutation; Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis; Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care; Access to patient medical chart for data collection; Willing and able to provide written informed consent and privacy authorization for the release of personal health information.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival of advanced NSCLC in Latin America | Time from randomization or initiation of treatment to patient death | Annually, during 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC | Description of the socioeconomical characteristics of the Latin America population with newly advanced NSCLC | Annually, during 3 years | 
| Description of pathological profile of advanced NSCLC | Analysis of histology and molecular markers of advanced NSCLC | Annually, during 3 years | 
| Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC | Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC | Annually, during 3 years | 
| Description of the treatment responses | Description of the treatment responses | Annually, during 3 years | 
| Description of Treatment discontinuation | Description of the reasons for treatment discontinuation | Annually, during 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Lung Cancer